Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sato to Enhance Main Brands, Promote Strategic Alliances
February 7, 2005
- 1st 3 Qtrs Business Results
February 7, 2005
- OTC NEWS IN BRIEF
February 7, 2005
- NEW PRODUCTS
February 7, 2005
- 1st 3 Qtrs Business Results
February 7, 2005
- Oxaliplatin Recommended for Approval
February 7, 2005
- MEDICAL DEVICE NEWS IN BRIEF
February 7, 2005
- Use of 3 Unapproved Drugs to Be Allowed under New Framework
February 7, 2005
- DIAGNOSTIC NEWS IN BRIEF
February 7, 2005
- Sosei, Abgenix Jointly Identify Lead Antibodies
February 7, 2005
- Mochida to Beef Up Split-off Houses
February 7, 2005
- Thalidomide Given Orphan Status
February 7, 2005
- Ryukinkyo's Model Contracts Need Revisions: EAD Director
February 7, 2005
- Insurance Rate to Differ in Each Pref.: Proposal
February 7, 2005
- REGULATORY NEWS IN BRIEF
February 7, 2005
- Aiming at an Over 4% Market Share by 2007: Mr Baba of Novartis
February 7, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 7, 2005
- BULLETIN
February 7, 2005
- AnGes MG to Jointly Research on Gene Therapy with Univ. of Tokyo Hospital
February 7, 2005
- Nakakita to Consolidate Its Position as Regional Wholesaler
February 7, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…